Abstracts tagged "Clinical Response and ethnic studies"

Abstract Number: 2378 • 2014 ACR/ARHP Annual Meeting
Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 Months Despite Infrequent Use of Biologic Therapies
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Sharon Dowell⁴, Luis R. Espinoza⁵, Edward Treadwell⁶, Theresa Lawrence-Ford⁷, Yvonne Sherrer⁸, Angelia Mosley-WIlliams⁹, Rodolfo Perez Alamino¹⁰, Ignacio Garcia-Valladares¹¹, Akgun Ince¹², Mercedes Quinones¹³, Chunqiao Luo³, Adrian Godoy⁴ and John Amatruda¹⁴, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁴Division of Rheumatology, Howard University, Washington, DC, ⁵Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁶Dept Medicine Div of Rheum, E Carolina Univ Sch of Med, Greenville, NC, ⁷North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁸Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁹Rheumatology, Detroit VAMC, Detroit, MI, ¹⁰internal Medicine, LSUHSC, New Orleans, LA, ¹¹Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³Division of Rheumatology, Howard University Hospital, Washington, DC, ¹⁴Rheumatology, Howard University, Washington, DC
Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 months Despite Infrequent Use of Biologic Therapies. Background/Purpose: Ethnic minorities with rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].